

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | TNF-α ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thalidomide | ✔ | E3 Ligase | 98% | ||||||||||||||||
| GSK2982772 |
++
human RIP1, IC50: 16 nM |
99%+ | |||||||||||||||||
| QNZ |
++++
TNF-α, IC50: 7 nM |
NF-κB | 99%+ | ||||||||||||||||
| Lenalidomide |
+++
TNF-α, IC50: 13 nM |
99% | |||||||||||||||||
| Pomalidomide |
+++
TNF-α, IC50: 13 nM |
98% | |||||||||||||||||
| GSK481 | ✔ | 99%+ | |||||||||||||||||
| Apremilast |
++
TNF-α, IC50: 77 nM |
98% | |||||||||||||||||
| Necrostatin-1 |
+
RIP1, EC50: 490 nM |
99%+ | |||||||||||||||||
| Acetylcysteine | ✔ | 98% | |||||||||||||||||
| Adalimumab | ✔ | 98% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 描述 | TNF-related apoptosis-inducing ligand (TRAIL, APO2L) is a member of the TNF cytokine superfamily,and is involved in pathogenesis of and/or possible treatment approaches for a variety of diseases including but not limited to cancer, obesity, diabetes, rheumatoid arthritis, and neurodegenerative diseases[2]. TRAIL secreted from natural killer (NK) cells binds to death receptors (DR4 or DR5). Bioymifi is an activator of the TRAIL receptor DR5 for cancer therapy. Bioymifi bound the extracellular domain (ECD) of DR5 with a Kd of 1.2 μM[3]. Human glioblastoma cells T98G cells, lung cancer cell lines H460 and H1155, the cervical cancer cell line HeLa, the osteosarcoma cell line U2OS, the pancreatic carcinoma cell line Miapaca and the colon cancer cell line HT29 showed single-agent sensitivity to bioymifi which is dependent on caspase-8[3]. Caspase-3 was rapidly activated as early as 2 h after bioymifi treatment (5 μM) of T98G cells and its activity was markedly increased after 8 h of treatment[3]. |
| 作用机制 | Bioymifi bound the extracellular domain (ECD) of DR5. |
| Concentration | Treated Time | Description | References | |
| 293T cells | 2 μM | 24 h | To detect the effect of Bioymifi on AGE-induced β-catenin/TCF transcriptional activity, KDR and HDAC9 promoter activity. The results showed that Bioymifi significantly reduced these activities | Cell Commun Signal. 2024 Mar 15;22(1):182. |
| HUVECs | 2 μM | 24 h | To detect the effect of Bioymifi on AGE-induced β-catenin Y142 phosphorylation. The results showed that Bioymifi significantly reduced the phosphorylation level of β-catenin Y142 | Cell Commun Signal. 2024 Mar 15;22(1):182. |
| intestinal organoids | 100 nM | 72 h | promoted organoid growth and the expression of ISC and intestinal epithelial cell marker genes | Cell Death Dis. 2024 Jan 10;15(1):27. |
| Adult mouse cardiac fibroblasts (AMCFs) | 1 µM | 24 h | Bioymifi increased BrdU incorporation in WT AMCFs but not in DR5KO AMCFs, indicating enhanced fibroblast proliferation via DR5-mediated mechanisms. | Front Cardiovasc Med. 2021 Aug 30;8:699102. |
| Neonatal rat ventricular fibroblasts (NRVFs) | 1 µM | 24 h | Bioymifi activation of DR5 did not induce apoptosis but increased proliferation via ERK1/2 signaling. | Front Cardiovasc Med. 2021 Aug 30;8:699102. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.02mL 0.40mL 0.20mL |
10.11mL 2.02mL 1.01mL |
20.23mL 4.05mL 2.02mL |
|
| CAS号 | 1420071-30-2 |
| 分子式 | C22H12BrN3O4S |
| 分子量 | 494.32 |
| SMILES Code | O=C(NC1=O)C2=C1C=CC(C3=CC=C(O3)/C=C(SC4=N)/C(N4C5=CC=C(C=C5)Br)=O)=C2 |
| MDL No. | MFCD28118988 |
| 别名 | DR5 Activator |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, 2-8°C |
| 溶解方案 |
DMSO: 12 mg/mL(24.28 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1